Higher baseline sPD-L1 levels in patients with glioma treated with radiotherapy were associated with poorer PFS and OS (90), and high sPD-L1 was considered a biomarker of poor prognosis in HCC patients undergoing curative treatment (91). Here, SPDL1 is linked to glioma.